Slart Riemer H J A, Punda Marija, Ali Dalal S, Bazzocchi Alberto, Bock Oliver, Camacho Pauline, Carey John J, Colquhoun Anita, Compston Juliet, Engelke Klaus, Erba Paola A, Harvey Nicholas C, Krueger Diane, Lems Willem F, Lewiecki E Michael, Morgan Sarah, Moseley Kendall F, O'Brien Christopher, Probyn Linda, Rhee Yumie, Richmond Bradford, Schousboe John T, Shuhart Christopher, Ward Kate A, Van den Wyngaert Tim, Zhang-Yin Jules, Khan Aliya A
Medical Imaging Centre, Department of Nuclear Medicine & Molecular Imaging (EB50), University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO 9700 RB, Groningen, The Netherlands.
Department of Oncology and Nuclear Medicine, University Hospital Centre Sestre Milosrdnice, Vinogradska 29, Zagreb, Croatia.
Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):539-563. doi: 10.1007/s00259-024-06912-6. Epub 2024 Sep 24.
The introduction of dual-energy X-ray absorptiometry (DXA) technology in the 1980s revolutionized the diagnosis, management and monitoring of osteoporosis, providing a clinical tool which is now available worldwide. However, DXA measurements are influenced by many technical factors, including the quality control procedures for the instrument, positioning of the patient, and approach to analysis. Reporting of DXA results may be confounded by factors such as selection of reference ranges for T-scores and Z-scores, as well as inadequate knowledge of current standards for interpretation. These points are addressed at length in many international guidelines but are not always easily assimilated by practising clinicians and technicians. Our aim in this report is to identify key elements pertaining to the use of DXA in clinical practice, considering both technical and clinical aspects. Here, we discuss technical aspects of DXA procedures, approaches to interpretation and integration into clinical practice, and the use of non-bone mineral density measurements, such as a vertebral fracture assessment, in clinical risk assessment.
20世纪80年代双能X线吸收法(DXA)技术的引入彻底改变了骨质疏松症的诊断、管理和监测方式,提供了一种现已在全球范围内可用的临床工具。然而,DXA测量受许多技术因素影响,包括仪器的质量控制程序、患者的体位以及分析方法。DXA结果的报告可能会因T值和Z值参考范围的选择以及对当前解释标准了解不足等因素而混淆。许多国际指南详细阐述了这些要点,但临床医生和技术人员并不总是容易理解。本报告的目的是确定临床实践中与DXA使用相关的关键要素,同时考虑技术和临床方面。在此,我们讨论DXA程序的技术方面、解释和融入临床实践的方法,以及在临床风险评估中使用非骨密度测量(如椎体骨折评估)的情况。
Eur J Nucl Med Mol Imaging. 2025-1
Arch Osteoporos. 2020-1-2
J Clin Endocrinol Metab. 2020-12-1
Semin Musculoskelet Radiol. 2016-7
Curr Opin Rheumatol. 2011-7
J Funct Morphol Kinesiol. 2025-7-11
Bioengineering (Basel). 2025-5-28
J Endocrinol Invest. 2024-3
Osteoporos Int. 2023-12
J Am Coll Radiol. 2022-11